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Purpose of the study
There is concern that human immunodeficiency virus
(HIV) infection and the use of highly active antiretro-
viral therapy lead to cumulative toxicity. Tenofovir
(TDF) is the first choice for most subjects. Even if it has
a safe metabolic profile, much attention has been fixed
on kidney tubular function and regulation of phosphate
metabolism. We performed this study to evaluate the
role of a TDF based regimen has on renal tubular over
time.
Methods
Prospective, cross-sectional, single centre study was car-
ried out. 121 HIV-1-infected patients were consecutively
enrolled in six groups based on duration of TDF exposi-
tion: G0, from 6 to 12 months; G1 from 13 to 24
months; G2 from 25 to 36 months; G3 from 37 to 48
months; G4 more than 48 months and G5 under
HAART but never exposed to TDF. Glomerular func-
tion was assessed using creatinine clearance (CrCL) cal-
culated by MDRD. Tubular function was assessed using
fractional excretion ratio of phosphate and normalized
renal threshold phosphate concentration. Demographic,
CD4, serum phosphate levels, viral load were collected.
Summary of results
A total of 121 consecutive HIV-1-infected patients were
analyzed: 15 in G0, 11 in G1, 14 in G2, 32 in G3, 35 in
G4 and 14 in G5. Mean of TDF exposure was 10.26,
21.4, 36.2, 47.3 and 67.4 months in G0, G1, G2, G3 and
G4 respectively. There was no statistically significant dif-
ference of mean values of FEP(11.2, 10.3, 8.4, 9.8, 11.1
and 10% in G0, G1, G2, G3, G4 and G5 respectively),
TmPO4/GFR (3.5, 3.5, 3.6, 3.6, 3.4 and 3.4 mg/dl in G0,
G1, G2, G3, G4 and G5 respectively ), CrCL (102.2,
94.3, 92.9, 106.5, 103.1 and 101.6 ml/min/1.73m2 in G0,
G1, G2, G3, G4 and G5 respectively) and serum phos-
phate levels (3.4, 3.3, 3.1, 3.5, 3.3 and 3.4 in G0, G1, G2,
G3, G4 and G5 respectively) between groups. Moreover,
we did not find correlation of FEP (r:0.04, p:0.6) and
TmPO4/GFR (r:0.05, p:0.5) with duration of TDF
therapy.
Conclusions
Treatment with TDF is not associated with altered kid-
ney tubular function and serum phosphate levels over
time.
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